ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

The Ideal Way to Use Quizartinib to Treat AML

Mark J. Levis, MD, PhD
Published Online:6:14 PM, Tue January 21, 2014
Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Clinical Pearls:
  • The ideal way to use a FLT3 inhibitor is to introduce it upfront with induction therapy in a newly diagnosed patient with FLT3-ITD AML
  • Studies using “not as effective” FLT3 inhibitors still show a considerable amount of efficacy with this procedure
  • Patients should be treated into remission until the patient can receive an allogeneic transplant and then a FLT3 inhibitor
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.